evidence table
Inulin Gut Microbiome Meta-Analysis Evidence Table
Structured evidence table for Inulin Gut Microbiome Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Inulin Gut Microbiome Meta-Analysis | The most common causes associated with LC are hepatitis C, followed by alcohol consumption, hepatitis B, and metabolic liver diseases (). | 1 | Wang Yi (2026) | The Efficacy of Gut Microbiome–Modulating Therapies on Liver Cirrhosis: A Systematic Review and Network Meta-Analysis |
| Inulin Gut Microbiome Meta-Analysis | Research indicates that LC is associated with significant intestinal barrier dysfunction, which parallels the progression of the disease. | 1 | Wang Yi (2026) | The Efficacy of Gut Microbiome–Modulating Therapies on Liver Cirrhosis: A Systematic Review and Network Meta-Analysis |
| Inulin Gut Microbiome Meta-Analysis | The gut microbiome and barrier dysfunction are directly involved in the pathogenesis of compensated LC, and both are associated with the frequency and severity of complications in decompensated cirrhosis, such as bacterial infections and hepatic encephalopathy (HE) (). | 1 | Wang Yi (2026) | The Efficacy of Gut Microbiome–Modulating Therapies on Liver Cirrhosis: A Systematic Review and Network Meta-Analysis |
| Inulin Gut Microbiome Meta-Analysis | 1 2 3 4 5 6 8 Liver cirrhosis (LC) is the outcome of the long-term progression of various chronic liver diseases, characterized by persistent inflammation, and is widely prevalent worldwide (). | 1 | Wang Yi (2026) | The Efficacy of Gut Microbiome–Modulating Therapies on Liver Cirrhosis: A Systematic Review and Network Meta-Analysis |
| Inulin Gut Microbiome Meta-Analysis | 1 2 3 4 5 6 5 Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the dominant form of chronic liver disease worldwide and should be understood not as an isolated hepatic disorder but as a liver-centred expression of systemic metabolic dysfunction []. | 3 | Acierno Carlo (2026) | Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation |
| Inulin Gut Microbiome Meta-Analysis | Epidemiological data indicate that MASLD patients carry a significantly elevated risk of incident type 2 diabetes, a cardiovascular risk that exceeds liver-related mortality in many cohorts, and a meaningful lifetime risk of hepatocellular carcinoma even in the absence of cirrhosis—underscoring the systemic clinical consequences of the condition [,]. | 3 | Acierno Carlo (2026) | Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation |
| Inulin Gut Microbiome Meta-Analysis | This multidimensional risk profile is what makes MASLD clinically consequential: it is highly prevalent, biologically heterogeneous, and embedded within a broader cardiometabolic continuum []. | 3 | Acierno Carlo (2026) | Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation |
Source documents